Abstract: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.

Abstract: A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.

Abstract: The present invention is directed to a novel short term slow release drug delivery system, preferably for solid oral dosage forms of water-soluble, alkaline salts of alkali metals and alkaline earth metals comprising polyvinylpyrrolidone and CPAA and preferably a wax component.

Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.

Abstract: A vitamin and mineral supplement containing ULTRADENSE™ calcium citrate and carbonyl iron for use in humans. Calcium in the form of citrate enhances absorption of iron, zinc, and magnesium. ULTRADENSE™ calcium citrate provides more bioavailable calcium than usual preparations of calcium citrate. Carbonyl iron provides iron in a form that significantly reduces the risk to children of accidental iron poisoning from formulations that provide iron in salt form. The supplement may further contain a number of vitamins and minerals in a tablet that is elegantly small, weighing about 1.5-1.6 g. The small size allows ease of swallowing and encourages patient acceptability. Methods of making such a supplement and methods of treating maladies in need of vitamin and mineral supplementation are provided.

Abstract: Methods of controlling calcium intake and phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a calcium glutarate compound. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to increase available calcium and contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.

Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.

Abstract: A composition useful as a dietary supplement for providing potassium, calcium, and citrate is presented, as well as processes for producing the composition, and methods for using the composition as a dietary supplement. Administration of the composition counters bone loss associated with aging or menopause by providing bioavailable calcium and, simultaneously, delivering alkali load. In addition, administration of the composition produces a substantial increase in urinary citrate, which counters kidney-stone formation.

Abstract: A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.

Abstract: A combination seal and constricting device and method of use for the external treatment of impotence is provided. The subject device is made of a pliable elastomeric material and is characterized by a centrally disposed cylindrical collar connected at one end thereof to a radially extending skirt having a forwardly facing, annular, elastomeric seating and sealing surface and a rearwardly facing surface substantially flush with one end of said collar. When used in combination with a conventional vacuum erection device, the combination seal and constricting device is positioned at the open end of the evacuation cylinder of the conventional vacuum erection device with the radially extending skirt flush between the open end of the cylinder and the user's groin. In this position, the subject device aids in establishing and maintaining a substantially airtight seal around the open end of the cylinder and the base of the penis during evacuation pumping.

Abstract: A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.

Abstract: One aspect of the present invention includes the novel compound having the formula:Ca.sub.2 (OOC--CH.sub.2 --COHCOO-CH.sub.2 COO)(CH.sub.3 CHOH-COO)In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition.In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate.

Abstract: A dual mineral salt consisting essentially of magnesium, potassium and citrate. A method for manufacturing the subject salt in a form having a bulk density ranging from about 1.0 g/cc to about 1.3 g/cc is also disclosed, and the use of the subject salt as a dietary supplement are also disclosed.

Abstract: A novel slow-release sodium fluoride preparation and its use. Such slow-release sodium preparation comprises carnauba wax and talc and may be used to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. Gastrointestinal side effects are minimized by limiting the amount of fluoride released in the stomach and rheumatic complications are reduced by avoiding toxic levels of fluoride is serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.

Abstract: A dual mineral salt consisting essentially of magnesium, potassium and citrate. A method for manufacturing the subject salt in a form having a bulk density ranging from about 1.0 g/cc to about 1.3 g/cc is also disclosed, and the use of the subject salt as a dietary supplement are also disclosed.

Abstract: The present invention comprises a composition of matter consisting essentially of citric acid and one or more calcium compounds selected from the group consisting of calcium hydroxide, calcium carbonate and calcium oxide. The composition of matter is preferably a substantially dry mixture which may be used, for example, as a powder for making an "instant" beverage of potable liquid. A preferred calcium compound/citric acid molar ratio in the composition of matter of the present invention is between about 0.6 and about 1.5.In a most preferred embodiment, the composition of matter of the present invention consists essentially of calcium hydroxide and citric acid having a calcium compound/citric acid or calcium hydroxide/citric acid molar ratio of about 1.25.The composition of matter of the present invention has a utility demostrated by dissolution in water to form a liquid dietary calcium supplement comprising soluble calcium citrate.

Abstract: A calcium citrate composition having a bulk density greater than about 1.1 g/cc. Citric acid and a calcium compound are mixed to produce a mixture having a calcium compound/citric acid molar ratio of about 1.5. A hydrated mixture percent is produced by agitatively adding water to the mixture, although when desired the calcium compound, citric acid and water mayBACKGROUND OF THE INVENTIONA portion of the development of the present invention was supported by Grant No. P01-AM 20543 from the United States Government, National Institutes of Health.

Abstract: A novel use for a slow-release sodium fluoride preparation. Such slow-release sodium preparation is shown to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. It minimizes gastrointestinal side effects by limiting the amount of fluoride released in the stomach and it reduces rheumatic complications by avoiding toxic levels of fluoride in serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.